SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
September 28, 2022
Date of Report (Date of earliest event reported)
BIOAFFINITY TECHNOLOGIES, INC.
(Exact name of registrant as specified in its charter)
(State or other jurisdiction
22211 W Interstate 10
San Antonio, Texas 78257
(Address of principal executive offices and Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|☐||Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)|
|☐||Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)|
|☐||Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))|
|☐||Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e- 4(c))|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
|Title of each class||Trading Symbol(s)||Name of each exchange on which registered|
|Common Stock, par value $.007 per share||BIAF||The Nasdaq Stock Market LLC|
|Tradeable Warrants to purchase Common Stock||BIAFW||The Nasdaq Stock Market LLC|
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01. Other Events.
Recent Press Release
On September 28, 2022, the Company issued a press releases announcing that it had received additional proceeds from the exercise of warrants issued by the Company in its recent public offering. The press release is filed as Exhibit 99.1 to this Form 8-K and is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
|99.1||Press Release of bioAffinity Technologies, Inc., dated September 28, 2022.|
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|BIOAFFINITY TECHNOLOGIES, INC.|
|By:||/s/ Maria Zannes|
|President and Chief Executive Officer|
Dated: September 28, 2022